Особенности течения желчнокаменной болезни у пациентов с неалкогольной жировой болезнью печени
Особенности течения желчнокаменной болезни у пациентов с неалкогольной жировой болезнью печени
Черкащенко Н.А., Ливзан М.А., Кролевец Т.С. Особенности течения желчнокаменной болезни у пациентов, страдающих неалкогольной жировой болезнью печени. Терапевтический архив. 2020; 92 (2): 48–54. DOI: 10.26442/ 00403660.2020.02.000550
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель исследования. Актуализация информации о коморбидности неалкогольной жировой болезни печени (НАЖБП) и желчнокаменной болезни (ЖКБ), оценка клинических, лабораторных данных, в том числе уровней инсулина, лептина и адипонектина, у лиц с НАЖБП в сочетании с ЖКБ.
Материалы и методы. Согласно дизайну нами проведено открытое сравнительное исследование с включением 169 пациентов с НАЖБП. Сформированы следующие группы сравнения: группа 1 (n=95) – пациенты с НАЖБП без ЖКБ, группа 2 (n=35) – пациенты с НАЖБП и ЖКБ с сохраненным желчным пузырем и группа 3 (n=39) – пациенты с НАЖБП и ЖКБ, перенесшие холецистэктомию.
Результаты. Выявлена высокая распространенность ишемической болезни сердца (ИБС) в группе пациентов с ЖКБ, перенесших холецистэктомию (χ2=6,198; p≤0,05), обнаружены положительные статистически значимые корреляционные взаимосвязи ЖКБ, перенесенной холецистэктомии с ИБС (rs=0,172, p≤0,05 и rs=0,241, p≤0,05, соответственно). Отмечалось статистически значимое снижение уровня общего билирубина и общего белка у пациентов 3-й группы (H=7,376, p≤0,03 и H=6,345, p≤0,04). Уровень лептина статистически значимо выше и положительно взаимосвязан с холецистэктомией по результатам сравнительного и корреляционного анализа (H=5,812, p≤0,05, rs=0,313, p≤0,05).
Заключение. Пациенты с НАЖБП, ЖКБ и перенесенной холецистэктомией имеют высокую распространенность ИБС; у пациентов, страдающих НАЖБП и ЖКБ, выявлен феномен инсулино- и лептинорезистентности, высокий уровень адипонектина; гиперлептинемия отмечена среди больных НАЖБП с ЖКБ после холецистэктомии.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, лептин, лептинорезистентность, холецистэктомия.
Materials and methods. According to the design, we conducted an open comparative study of 169 patients with NAFLD. The following comparison groups were formed: group 1 (n=95) – patients with NAFLD without GD, group 2 (n=35) – patients with NAFLD and GD and group 3 (n=39) – patients with NAFLD, GD and previous cholecystectomy.
Results. A high prevalence of coronary heart disease was found in the group of patients with GD and cholecystectomy (χ2=6.198, p≤0.05); positive, statistically significant correlation relationships of cholelithiasis, cholecystectomy with ischemic heart disease (rs=0.172, p≤0.05 and rs=0.241, p≤0.05, respectively). There was a statistically significant decrease in total bilirubin and total protein in patients of group 3 (H=7.376, p≤0.03 and H=6.345, p≤0.04). The level of leptin is statistically significantly higher and positively interrelated with cholecystectomy (H=5.812, p≤0.05, rs=0.313, p≤0.05).
Conclusion. Patients with NAFLD, GD and previous cholecystectomy have a high prevalence of coronary heart disease; the phenomenon of insulin and leptin resistance, high level of adiponectin were revealed in patients with NAFLD and gallstones; hyperleptinemia was observed among patients with NAFLD, GD after cholecystectomy.
Keywords: non-alcoholic fatty liver disease, gallstones disease, leptin, leptin resistance, cholecystectomy.
Материалы и методы. Согласно дизайну нами проведено открытое сравнительное исследование с включением 169 пациентов с НАЖБП. Сформированы следующие группы сравнения: группа 1 (n=95) – пациенты с НАЖБП без ЖКБ, группа 2 (n=35) – пациенты с НАЖБП и ЖКБ с сохраненным желчным пузырем и группа 3 (n=39) – пациенты с НАЖБП и ЖКБ, перенесшие холецистэктомию.
Результаты. Выявлена высокая распространенность ишемической болезни сердца (ИБС) в группе пациентов с ЖКБ, перенесших холецистэктомию (χ2=6,198; p≤0,05), обнаружены положительные статистически значимые корреляционные взаимосвязи ЖКБ, перенесенной холецистэктомии с ИБС (rs=0,172, p≤0,05 и rs=0,241, p≤0,05, соответственно). Отмечалось статистически значимое снижение уровня общего билирубина и общего белка у пациентов 3-й группы (H=7,376, p≤0,03 и H=6,345, p≤0,04). Уровень лептина статистически значимо выше и положительно взаимосвязан с холецистэктомией по результатам сравнительного и корреляционного анализа (H=5,812, p≤0,05, rs=0,313, p≤0,05).
Заключение. Пациенты с НАЖБП, ЖКБ и перенесенной холецистэктомией имеют высокую распространенность ИБС; у пациентов, страдающих НАЖБП и ЖКБ, выявлен феномен инсулино- и лептинорезистентности, высокий уровень адипонектина; гиперлептинемия отмечена среди больных НАЖБП с ЖКБ после холецистэктомии.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, лептин, лептинорезистентность, холецистэктомия.
________________________________________________
Materials and methods. According to the design, we conducted an open comparative study of 169 patients with NAFLD. The following comparison groups were formed: group 1 (n=95) – patients with NAFLD without GD, group 2 (n=35) – patients with NAFLD and GD and group 3 (n=39) – patients with NAFLD, GD and previous cholecystectomy.
Results. A high prevalence of coronary heart disease was found in the group of patients with GD and cholecystectomy (χ2=6.198, p≤0.05); positive, statistically significant correlation relationships of cholelithiasis, cholecystectomy with ischemic heart disease (rs=0.172, p≤0.05 and rs=0.241, p≤0.05, respectively). There was a statistically significant decrease in total bilirubin and total protein in patients of group 3 (H=7.376, p≤0.03 and H=6.345, p≤0.04). The level of leptin is statistically significantly higher and positively interrelated with cholecystectomy (H=5.812, p≤0.05, rs=0.313, p≤0.05).
Conclusion. Patients with NAFLD, GD and previous cholecystectomy have a high prevalence of coronary heart disease; the phenomenon of insulin and leptin resistance, high level of adiponectin were revealed in patients with NAFLD and gallstones; hyperleptinemia was observed among patients with NAFLD, GD after cholecystectomy.
Keywords: non-alcoholic fatty liver disease, gallstones disease, leptin, leptin resistance, cholecystectomy.
Список литературы
1. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Translat Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
2. Ивашкин В.Т., Маев И.В., Баранская Е.К. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):64-80 [Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.)] doi: 10.22416/1382-4376-2016-26-3-64-80
3. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-92. doi: 10.3748/wjg.v23.i36.6571
4. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
5. Дичева Д.Т., Кузнецова Е.И. Современные аспекты лечения пациентов с неалкогольной жировой болезнью печени. Consilium Medicum. 2018;20(8):20-3 [Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.)]. doi: 10.26442/2075-1753_2018.8.20-23
6. Гланц С. Медико-биологическая статистика. Пер. с англ. Ю.А. Данилова. М.: Практика, 1998. 459 с. [Glanc S. Biomedical statistics. Translate from English Yu.A. Danilov. Moscow: Praktika, 1998. 459 p. (In Russ.)].
7. Макарова Ю.В., Литвинова Н.В., Волошина Н.Б., Осипенко М.Ф. Динамика абдоминального болевого синдрома у больных желчнокаменной болезнью в процессе 10-летнего наблюдения. Journal of Siberian Medical Sciences. 2018;(4):54-66 [Makarova YuV, Litvinova NV, Voloshinа NB, Osipenko MF. Dynamics of abdominal pain syndrome in patients with cholelithiasis throughout the 10-year follow-up period. Journal of Siberian Medical Sciences. 2018;(4):54-66 (In Russ. and in Engl.)]. doi: 10.31549/2542-1174-2018-4-54-66
8. Zheng Y, Xu M, Li Y, Hruby A, et al. Gallstones and Risk of Coronary Heart Disease Prospective Analysis of 270 000 Menand Women From 3 US Cohorts and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997-2003. doi: 10.1161/ATVBAHA.116.307507
9. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. SCienTifiCReporTS. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
10. Amigo L, Husche C, Zanlungo S, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2011;31:52-64. doi: 10.1111/j.1478-3231.2010.02361.x
11. Zweers SJ, Booij K, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575-83. doi: 10.1002/hep.24702
12. Ивашкин В.Т., Охлобыстин А.В., Бордин Д.С. и др. Резолюция экспертного совета «Современный взгляд на проблему постхолецистэктомического синдрома». Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):96-108 [Ivashkin VT, Okhlobystin AV, Bordin DS, et al. Postcholecystectomy syndrome: the modern approach: resolution of Advisory council. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):96-108 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-6-96-108
13. Keren N, Konikoff FM, Paitan Y, Gabay G, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
14. Хатьков И.Е., Ливзан М.А., Осипенко М.Ф. и др. Профессиональное медицинское сообщество «Панкреатологический клуб». Российский консенсус по экзо- и эндокринной недостаточности поджелудочной железы после хирургического лечения. Терапевтический архив. 2018;90(8):13-26 [Khatkov IE, Livzan MA, Osipenko MF, et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Therapeutic Archive. 2018;90(8):13-26 (In Russ.)].
15. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
16. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7)e41183:1-5.
17. Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):43-51 [Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (in Russ.)]
18. Опенко Т.Г. Роль адипокинов в патогенезе метаболического синдрома. Мир науки, культуры, образования. 2010;6-1:227-32 [Openko TG. The role of adipokines in the pathogenesis of metabolic syndrome. Mir Nauki, Kul'tury, Obrazovanija. 2010;6-1:227-32 (In Russ.)].
19. Stenvinkel P, Lonnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant. 1999;14:1103-12.
20. Кролевец Т.С., Ливзан М.А., Чебаненко Е.В., Мазур И.И. и др. Прогностическая модель неинвазивной оценки формирования и прогрессирования фиброза печени у пациентов с неалкогольной жировой болезнью печени. Современные проблемы науки и образования. 2018;(3) [Krolevets TS, Livzan MA, Chebanenko EV, Mazur II, et al. Predictive model of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty liver disease. Modern Problems of Science and Education. 2018;(3) (In Russ.)]. Available at: https://www.science-education.ru/ru/article/view?id=27713
21. Zhang W, Telemaque-Potts S, Anderson PR, Wang Z, An Jie, et al. OR-2: Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens. 2002;15(S3):1A.
22. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Медицинский совет. 2015;13:58-63 [Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)]. doi: 10.21518/2079-701X-2015-13-58-63
23. Lei ZM, Ye MX, Fu WG, et al. Levels of serum leptin, cholecystokinin, plasma lipid and lipoprotein differ between patients with gallstone or/and those with hepatolithiasis. Hepatobiliary Pancreat Dis Int. 2008;7:65-9.
24. Mendez-Sanchez N, Bermejo-Martınez LB, Vinals Y, et al. Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol. 2005;11:6182-7. doi: 10.3748/wjg.v11.i39.6182
25. Misciagna G, Guerra V, DiLeo A. Insulin and gallstones: a population case control study in southern Italy. Gut. 2000;47(1):144-7. doi: 10.1136/gut.47.1.144
26. Kim JM, Lee HL, Moon W. Association between insulin, insulinresistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-7.
27. Chang Y, Sung E, Ryu S, et al. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23:644-50. doi: 10.3346/jkms.2008.23.4.644
28. Sarac S, Atamer A, Atamer Y, et al. Leptin levels and lipoprotein profiles in patients with cholelithiasis. J Intern Med Res. 2015;43(3):385-92. doi: 10.1177/0300060514561134
29. Goldblatt MI, Swartz-Basile DA, Svatek CL, et al. Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg. 2002;6:438-42.
30. Yarandi SS, Hebbar G, Sauer CG, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269-75. doi: 10.1016/j.nut.2010.07.004
31. De Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One. 2012;7:e32967. doi: 10.1371/journal.pone.0032967
32. Florian V, Caroline F, Francis C, et al. Leptin modulates enteric neurotransmission in the rat proximal colon: An in vitro study. Regul Pept. 2013;185:73-8. doi: 10.1016/j.regpep.2013.06.010
33. Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H. Leptin regulates gallbladder genes related to absorption and secretion. Am J Physiol Gastrointest. Liver Physiol. 2007;293(1):G84-G90. doi: 10.1152/ajpgi.00389.2006
34. Graewin SJ, Kiely JM, Lu D, et al. Leptin regulates gallbladder genes related to gallstone pathogenesis in leptin-deficient mice. J Am Coll Surg. 2008;206:503-10. doi: 10.1016/j.jamcollsurg.2007.09.015
35. Звенигородская Л.А. Метаболический синдром: основы патогенеза, исследования в будущем. Экспериментальная и клиническая гастроэнтерология. 2007;(1):5-7 [Zvenigorodskaja LA. Metabolic syndrome: the basics of pathogenesis, future research. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2007;(1):5-7 (In Russ.)].
36. Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы. Артериальная гипертензия. 2011;17(3):203-8 [Drapkina OM, Korneeva ON, Palatkina LO. Adipokines and cardiovascular diseases: impact on pathogenesis and therapeutic perspectives. Arterial'naja Gipertenzija. 2011;17(3):203-8 (In Russ.)]. doi: 10.18705/1607-419X-2011-17-3-203-208
37. López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest. 2014;18(1):37-45. doi: 10.1515/hmbci-2013-0053
38. Wang SN, Yeh YT, Yu ML. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest. 2006;36(3):176-80. doi: 10.1111/j.1365-2362.2006.01611.x
39. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014;20(23):7277-85. doi: 10.3748/wjg.v20.i23.7277
2. Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.) doi: 10.22416/1382-4376-2016-26-3-64-80
3. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-92. doi: 10.3748/wjg.v23.i36.6571
4. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
5. Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.) doi: 10.26442/2075-1753_2018.8.20-23
6. Glanc S. Biomedical statistics. Translate from English Yu.A. Danilov. Moscow: Praktika, 1998. 459 p. (In Russ.)
7. Makarova YuV, Litvinova NV, Voloshinа NB, Osipenko MF. Dynamics of abdominal pain syndrome in patients with cholelithiasis throughout the 10-year follow-up period. Journal of Siberian Medical Sciences. 2018;(4):54-66 (In Russ. and in Engl.) doi: 10.31549/2542-1174-2018-4-54-66
8. Zheng Y, Xu M, Li Y, Hruby A, et al. Gallstones and Risk of Coronary Heart Disease Prospective Analysis of 270 000 Menand Women From 3 US Cohorts and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997-2003. doi: 10.1161/ATVBAHA.116.307507
9. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. SCienTifiCReporTS. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
10. Amigo L, Husche C, Zanlungo S, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2011;31:52-64. doi: 10.1111/j.1478-3231.2010.02361.x
11. Zweers SJ, Booij K, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575-83. doi: 10.1002/hep.24702
12. Ivashkin VT, Okhlobystin AV, Bordin DS, et al. Postcholecystectomy syndrome: the modern approach: resolution of Advisory council. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):96-108 (In Russ.) doi: 10.22416/1382-4376-2017-27-6-96-108
13. Keren N, Konikoff FM, Paitan Y, Gabay G, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
14. Khatkov IE, Livzan MA, Osipenko MF, et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Therapeutic Archive. 2018;90(8):13-26 (In Russ.)
15. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
16. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7)e41183:1-5.
17. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (in Russ.)
18. Openko TG. The role of adipokines in the pathogenesis of metabolic syndrome. Mir Nauki, Kul'tury, Obrazovanija. 2010;6-1:227-32 (In Russ.)
19. Stenvinkel P, Lonnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant. 1999;14:1103-12.
20. Krolevets TS, Livzan MA, Chebanenko EV, Mazur II, et al. Predictive model of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty liver disease. Modern Problems of Science and Education. 2018;(3) (In Russ.) Available at: https://www.science-education.ru/ru/article/view?id=27713
21. Zhang W, Telemaque-Potts S, Anderson PR, Wang Z, An Jie, et al. OR-2: Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens. 2002;15(S3):1A.
22. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.) doi: 10.21518/2079-701X-2015-13-58-63
23. Lei ZM, Ye MX, Fu WG, et al. Levels of serum leptin, cholecystokinin, plasma lipid and lipoprotein differ between patients with gallstone or/and those with hepatolithiasis. Hepatobiliary Pancreat Dis Int. 2008;7:65-9.
24. Mendez-Sanchez N, Bermejo-Martınez LB, Vinals Y, et al. Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol. 2005;11:6182-7. doi: 10.3748/wjg.v11.i39.6182
25. Misciagna G, Guerra V, DiLeo A. Insulin and gallstones: a population case control study in southern Italy. Gut. 2000;47(1):144-7. doi: 10.1136/gut.47.1.144
26. Kim JM, Lee HL, Moon W. Association between insulin, insulinresistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-7.
27. Chang Y, Sung E, Ryu S, et al. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23:644-50. doi: 10.3346/jkms.2008.23.4.644
28. Sarac S, Atamer A, Atamer Y, et al. Leptin levels and lipoprotein profiles in patients with cholelithiasis. J Intern Med Res. 2015;43(3):385-92. doi: 10.1177/0300060514561134
29. Goldblatt MI, Swartz-Basile DA, Svatek CL, et al. Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg. 2002;6:438-42.
30. Yarandi SS, Hebbar G, Sauer CG, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269-75. doi: 10.1016/j.nut.2010.07.004
31. De Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One. 2012;7:e32967. doi: 10.1371/journal.pone.0032967
32. Florian V, Caroline F, Francis C, et al. Leptin modulates enteric neurotransmission in the rat proximal colon: An in vitro study. Regul Pept. 2013;185:73-8. doi: 10.1016/j.regpep.2013.06.010
33. Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H. Leptin regulates gallbladder genes related to absorption and secretion. Am J Physiol Gastrointest. Liver Physiol. 2007;293(1):G84-G90. doi: 10.1152/ajpgi.00389.2006
34. Graewin SJ, Kiely JM, Lu D, et al. Leptin regulates gallbladder genes related to gallstone pathogenesis in leptin-deficient mice. J Am Coll Surg. 2008;206:503-10. doi: 10.1016/j.jamcollsurg.2007.09.015
35. Zvenigorodskaja LA. Metabolic syndrome: the basics of pathogenesis, future research. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2007;(1):5-7 (In Russ.)
36. Drapkina OM, Korneeva ON, Palatkina LO. Adipokines and cardiovascular diseases: impact on pathogenesis and therapeutic perspectives. Arterial'naja Gipertenzija. 2011;17(3):203-8 (In Russ.) doi: 10.18705/1607-419X-2011-17-3-203-208
37. López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest. 2014;18(1):37-45. doi: 10.1515/hmbci-2013-0053
38. Wang SN, Yeh YT, Yu ML. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest. 2006;36(3):176-80. doi: 10.1111/j.1365-2362.2006.01611.x
39. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014;20(23):7277-85. doi: 10.3748/wjg.v20.i23.7277
2. Ивашкин В.Т., Маев И.В., Баранская Е.К. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):64-80 [Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.)] doi: 10.22416/1382-4376-2016-26-3-64-80
3. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-92. doi: 10.3748/wjg.v23.i36.6571
4. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
5. Дичева Д.Т., Кузнецова Е.И. Современные аспекты лечения пациентов с неалкогольной жировой болезнью печени. Consilium Medicum. 2018;20(8):20-3 [Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.)]. doi: 10.26442/2075-1753_2018.8.20-23
6. Гланц С. Медико-биологическая статистика. Пер. с англ. Ю.А. Данилова. М.: Практика, 1998. 459 с. [Glanc S. Biomedical statistics. Translate from English Yu.A. Danilov. Moscow: Praktika, 1998. 459 p. (In Russ.)].
7. Макарова Ю.В., Литвинова Н.В., Волошина Н.Б., Осипенко М.Ф. Динамика абдоминального болевого синдрома у больных желчнокаменной болезнью в процессе 10-летнего наблюдения. Journal of Siberian Medical Sciences. 2018;(4):54-66 [Makarova YuV, Litvinova NV, Voloshinа NB, Osipenko MF. Dynamics of abdominal pain syndrome in patients with cholelithiasis throughout the 10-year follow-up period. Journal of Siberian Medical Sciences. 2018;(4):54-66 (In Russ. and in Engl.)]. doi: 10.31549/2542-1174-2018-4-54-66
8. Zheng Y, Xu M, Li Y, Hruby A, et al. Gallstones and Risk of Coronary Heart Disease Prospective Analysis of 270 000 Menand Women From 3 US Cohorts and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997-2003. doi: 10.1161/ATVBAHA.116.307507
9. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. SCienTifiCReporTS. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
10. Amigo L, Husche C, Zanlungo S, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2011;31:52-64. doi: 10.1111/j.1478-3231.2010.02361.x
11. Zweers SJ, Booij K, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575-83. doi: 10.1002/hep.24702
12. Ивашкин В.Т., Охлобыстин А.В., Бордин Д.С. и др. Резолюция экспертного совета «Современный взгляд на проблему постхолецистэктомического синдрома». Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):96-108 [Ivashkin VT, Okhlobystin AV, Bordin DS, et al. Postcholecystectomy syndrome: the modern approach: resolution of Advisory council. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):96-108 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-6-96-108
13. Keren N, Konikoff FM, Paitan Y, Gabay G, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
14. Хатьков И.Е., Ливзан М.А., Осипенко М.Ф. и др. Профессиональное медицинское сообщество «Панкреатологический клуб». Российский консенсус по экзо- и эндокринной недостаточности поджелудочной железы после хирургического лечения. Терапевтический архив. 2018;90(8):13-26 [Khatkov IE, Livzan MA, Osipenko MF, et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Therapeutic Archive. 2018;90(8):13-26 (In Russ.)].
15. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
16. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7)e41183:1-5.
17. Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7):43-51 [Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (in Russ.)]
18. Опенко Т.Г. Роль адипокинов в патогенезе метаболического синдрома. Мир науки, культуры, образования. 2010;6-1:227-32 [Openko TG. The role of adipokines in the pathogenesis of metabolic syndrome. Mir Nauki, Kul'tury, Obrazovanija. 2010;6-1:227-32 (In Russ.)].
19. Stenvinkel P, Lonnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant. 1999;14:1103-12.
20. Кролевец Т.С., Ливзан М.А., Чебаненко Е.В., Мазур И.И. и др. Прогностическая модель неинвазивной оценки формирования и прогрессирования фиброза печени у пациентов с неалкогольной жировой болезнью печени. Современные проблемы науки и образования. 2018;(3) [Krolevets TS, Livzan MA, Chebanenko EV, Mazur II, et al. Predictive model of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty liver disease. Modern Problems of Science and Education. 2018;(3) (In Russ.)]. Available at: https://www.science-education.ru/ru/article/view?id=27713
21. Zhang W, Telemaque-Potts S, Anderson PR, Wang Z, An Jie, et al. OR-2: Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens. 2002;15(S3):1A.
22. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Медицинский совет. 2015;13:58-63 [Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.)]. doi: 10.21518/2079-701X-2015-13-58-63
23. Lei ZM, Ye MX, Fu WG, et al. Levels of serum leptin, cholecystokinin, plasma lipid and lipoprotein differ between patients with gallstone or/and those with hepatolithiasis. Hepatobiliary Pancreat Dis Int. 2008;7:65-9.
24. Mendez-Sanchez N, Bermejo-Martınez LB, Vinals Y, et al. Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol. 2005;11:6182-7. doi: 10.3748/wjg.v11.i39.6182
25. Misciagna G, Guerra V, DiLeo A. Insulin and gallstones: a population case control study in southern Italy. Gut. 2000;47(1):144-7. doi: 10.1136/gut.47.1.144
26. Kim JM, Lee HL, Moon W. Association between insulin, insulinresistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-7.
27. Chang Y, Sung E, Ryu S, et al. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23:644-50. doi: 10.3346/jkms.2008.23.4.644
28. Sarac S, Atamer A, Atamer Y, et al. Leptin levels and lipoprotein profiles in patients with cholelithiasis. J Intern Med Res. 2015;43(3):385-92. doi: 10.1177/0300060514561134
29. Goldblatt MI, Swartz-Basile DA, Svatek CL, et al. Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg. 2002;6:438-42.
30. Yarandi SS, Hebbar G, Sauer CG, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269-75. doi: 10.1016/j.nut.2010.07.004
31. De Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One. 2012;7:e32967. doi: 10.1371/journal.pone.0032967
32. Florian V, Caroline F, Francis C, et al. Leptin modulates enteric neurotransmission in the rat proximal colon: An in vitro study. Regul Pept. 2013;185:73-8. doi: 10.1016/j.regpep.2013.06.010
33. Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H. Leptin regulates gallbladder genes related to absorption and secretion. Am J Physiol Gastrointest. Liver Physiol. 2007;293(1):G84-G90. doi: 10.1152/ajpgi.00389.2006
34. Graewin SJ, Kiely JM, Lu D, et al. Leptin regulates gallbladder genes related to gallstone pathogenesis in leptin-deficient mice. J Am Coll Surg. 2008;206:503-10. doi: 10.1016/j.jamcollsurg.2007.09.015
35. Звенигородская Л.А. Метаболический синдром: основы патогенеза, исследования в будущем. Экспериментальная и клиническая гастроэнтерология. 2007;(1):5-7 [Zvenigorodskaja LA. Metabolic syndrome: the basics of pathogenesis, future research. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2007;(1):5-7 (In Russ.)].
36. Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы. Артериальная гипертензия. 2011;17(3):203-8 [Drapkina OM, Korneeva ON, Palatkina LO. Adipokines and cardiovascular diseases: impact on pathogenesis and therapeutic perspectives. Arterial'naja Gipertenzija. 2011;17(3):203-8 (In Russ.)]. doi: 10.18705/1607-419X-2011-17-3-203-208
37. López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest. 2014;18(1):37-45. doi: 10.1515/hmbci-2013-0053
38. Wang SN, Yeh YT, Yu ML. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest. 2006;36(3):176-80. doi: 10.1111/j.1365-2362.2006.01611.x
39. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014;20(23):7277-85. doi: 10.3748/wjg.v20.i23.7277
________________________________________________
2. Ivashkin VT, Mayev IV, Baranskaya YeK, et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64-80 (In Russ.) doi: 10.22416/1382-4376-2016-26-3-64-80
3. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-92. doi: 10.3748/wjg.v23.i36.6571
4. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
5. Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.) doi: 10.26442/2075-1753_2018.8.20-23
6. Glanc S. Biomedical statistics. Translate from English Yu.A. Danilov. Moscow: Praktika, 1998. 459 p. (In Russ.)
7. Makarova YuV, Litvinova NV, Voloshinа NB, Osipenko MF. Dynamics of abdominal pain syndrome in patients with cholelithiasis throughout the 10-year follow-up period. Journal of Siberian Medical Sciences. 2018;(4):54-66 (In Russ. and in Engl.) doi: 10.31549/2542-1174-2018-4-54-66
8. Zheng Y, Xu M, Li Y, Hruby A, et al. Gallstones and Risk of Coronary Heart Disease Prospective Analysis of 270 000 Menand Women From 3 US Cohorts and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997-2003. doi: 10.1161/ATVBAHA.116.307507
9. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. SCienTifiCReporTS. 2017;7:15104. doi: 10.1038/s41598-017-15430-5
10. Amigo L, Husche C, Zanlungo S, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2011;31:52-64. doi: 10.1111/j.1478-3231.2010.02361.x
11. Zweers SJ, Booij K, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575-83. doi: 10.1002/hep.24702
12. Ivashkin VT, Okhlobystin AV, Bordin DS, et al. Postcholecystectomy syndrome: the modern approach: resolution of Advisory council. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):96-108 (In Russ.) doi: 10.22416/1382-4376-2017-27-6-96-108
13. Keren N, Konikoff FM, Paitan Y, Gabay G, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015;7:874-80. doi: 10.1111/1758-2229.12319
14. Khatkov IE, Livzan MA, Osipenko MF, et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Therapeutic Archive. 2018;90(8):13-26 (In Russ.)
15. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut Liver. 2014;8(3):313-7. doi: 10.5009/gnl.2014.8.3.313
16. Fracanzani AL, Valenti L, Russello M, et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(7)e41183:1-5.
17. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2018;155(7):43-51 (in Russ.)
18. Openko TG. The role of adipokines in the pathogenesis of metabolic syndrome. Mir Nauki, Kul'tury, Obrazovanija. 2010;6-1:227-32 (In Russ.)
19. Stenvinkel P, Lonnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant. 1999;14:1103-12.
20. Krolevets TS, Livzan MA, Chebanenko EV, Mazur II, et al. Predictive model of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty liver disease. Modern Problems of Science and Education. 2018;(3) (In Russ.) Available at: https://www.science-education.ru/ru/article/view?id=27713
21. Zhang W, Telemaque-Potts S, Anderson PR, Wang Z, An Jie, et al. OR-2: Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens. 2002;15(S3):1A.
22. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.) doi: 10.21518/2079-701X-2015-13-58-63
23. Lei ZM, Ye MX, Fu WG, et al. Levels of serum leptin, cholecystokinin, plasma lipid and lipoprotein differ between patients with gallstone or/and those with hepatolithiasis. Hepatobiliary Pancreat Dis Int. 2008;7:65-9.
24. Mendez-Sanchez N, Bermejo-Martınez LB, Vinals Y, et al. Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol. 2005;11:6182-7. doi: 10.3748/wjg.v11.i39.6182
25. Misciagna G, Guerra V, DiLeo A. Insulin and gallstones: a population case control study in southern Italy. Gut. 2000;47(1):144-7. doi: 10.1136/gut.47.1.144
26. Kim JM, Lee HL, Moon W. Association between insulin, insulinresistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-7.
27. Chang Y, Sung E, Ryu S, et al. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23:644-50. doi: 10.3346/jkms.2008.23.4.644
28. Sarac S, Atamer A, Atamer Y, et al. Leptin levels and lipoprotein profiles in patients with cholelithiasis. J Intern Med Res. 2015;43(3):385-92. doi: 10.1177/0300060514561134
29. Goldblatt MI, Swartz-Basile DA, Svatek CL, et al. Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg. 2002;6:438-42.
30. Yarandi SS, Hebbar G, Sauer CG, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269-75. doi: 10.1016/j.nut.2010.07.004
31. De Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One. 2012;7:e32967. doi: 10.1371/journal.pone.0032967
32. Florian V, Caroline F, Francis C, et al. Leptin modulates enteric neurotransmission in the rat proximal colon: An in vitro study. Regul Pept. 2013;185:73-8. doi: 10.1016/j.regpep.2013.06.010
33. Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H. Leptin regulates gallbladder genes related to absorption and secretion. Am J Physiol Gastrointest. Liver Physiol. 2007;293(1):G84-G90. doi: 10.1152/ajpgi.00389.2006
34. Graewin SJ, Kiely JM, Lu D, et al. Leptin regulates gallbladder genes related to gallstone pathogenesis in leptin-deficient mice. J Am Coll Surg. 2008;206:503-10. doi: 10.1016/j.jamcollsurg.2007.09.015
35. Zvenigorodskaja LA. Metabolic syndrome: the basics of pathogenesis, future research. Jeksperimental'naja i Klinicheskaja Gastrojenterologija = Experimental and Clinical Gastroenterology. 2007;(1):5-7 (In Russ.)
36. Drapkina OM, Korneeva ON, Palatkina LO. Adipokines and cardiovascular diseases: impact on pathogenesis and therapeutic perspectives. Arterial'naja Gipertenzija. 2011;17(3):203-8 (In Russ.) doi: 10.18705/1607-419X-2011-17-3-203-208
37. López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest. 2014;18(1):37-45. doi: 10.1515/hmbci-2013-0053
38. Wang SN, Yeh YT, Yu ML. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest. 2006;36(3):176-80. doi: 10.1111/j.1365-2362.2006.01611.x
39. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014;20(23):7277-85. doi: 10.3748/wjg.v20.i23.7277
Авторы
Н.А. Черкащенко1, М.А. Ливзан2, Т.С. Кролевец2
1 ФГБУЗ «Западно-Сибирский медицинский центр» ФМБА России, Омск, Россия;
2 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия.
1 West-Siberian Medical Center, Omsk, Russia;
2 Omsk State Medical University, Omsk, Russia
1 ФГБУЗ «Западно-Сибирский медицинский центр» ФМБА России, Омск, Россия;
2 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия.
________________________________________________
1 West-Siberian Medical Center, Omsk, Russia;
2 Omsk State Medical University, Omsk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.